Business of Cannabis is excited to announce the launch of German Cannabis Intel: Insights & Market Data, the inaugural report in our new quarterly series in partnership with Grünhorn.
Thanks to the latest, on-the-ground data from Grünhorn, our new regular snapshots will combine market-wide product data with the company’s own prescribing records to provide the most comprehensive overview available of Germany’s rapidly evolving medical cannabis market, all completely free.
Each edition will track everything from product availability and pricing trends to patient demographics and prescription patterns.
Hitting the ground running, our first edition reveals a market undergoing significant changes. Available products have quadrupled from approximately 400 in January 2024 to 1,992 by December 2025, while average listing prices have fallen from over €10 per gram in early 2023 to approximately €7-8 per gram by late 2025, a drop of nearly a third.
This fall in prices, the report shows, is being driven by a flood of imports from low-cost producers, oversupply in the market, and expiring products, which lead distributors and pharmacies to sell at below-market rates before products must be destroyed.
As the industry prepares for potentially significant changes to regulation surrounding medical cannabis prescriptions in the coming weeks, the timing could not be more critical.
Understanding actual market dynamics, what patients want, how they behave, which products succeed, and how prices are moving, is now even more critical for operators making strategic decisions.
Below are some key insights from the report, which you can download for free here
Consolidation around cheap, high-THC products
The data reveals clear patient preferences emerging. The majority of available products now cluster in specific price and potency ranges, with high-THC products at accessible price points dominating the market.
Meanwhile, a dramatic shift away from irradiated flowers is taking shape, seeing the share of irradiated flower products collapse from 40% in January 2024 to just 12% by December 2025, indicating both improving cultivation quality and strong patient preference for non-irradiated products.
Germany’s patient population may be older than you think
Grünhorn’s prescribing data challenges common assumptions about medical cannabis demographics. Patients aged 25-44 account for 61% of the patient base, while those aged 18-24 represent just 10%.
The data also reveals a direct correlation between patient age and both prescription size and potency, with older patients tending to consume stronger strains in higher volumes, potentially a signal of pain management requirements as a primary indication.
Geographic distribution tracks closely with Germany’s population distribution across federal states, with one notable exception that suggests untapped market potential in a major region.
Competition outweighs brand loyalty
With nearly 2,000 products now available, brand loyalty is becoming increasingly elusive. The report’s analysis of patient prescription patterns across multiple refills shows most patients switch brands after initial prescriptions, with loyalty declining even further over time.
The top 10 best-selling products reveal which suppliers are succeeding despite low loyalty, with Aurora’s Pedanios line and Grünhorn’s own branded products featuring prominently. However, the competitive dynamics suggest operators must maintain ongoing performance on price, quality, and availability rather than relying on established patient relationships.
The German Cannabis Intel: Insights & Market Data Q1 2026 report is available for free download from Business of Cannabis and Grünhorn.
